{"created":"2023-05-15T16:46:45.177730+00:00","id":23161,"links":{},"metadata":{"_buckets":{"deposit":"503434ed-cc45-4a1e-a985-21de5d385b97"},"_deposit":{"created_by":2,"id":"23161","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"23161"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00023161","sets":["73:74"]},"author_link":["97783","97775","97776","97785","97778","97784","97780","97781","97777","97782","97779"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2002-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"1076","bibliographicPageStart":"1072","bibliographicVolumeNumber":"25","bibliographic_titles":[{"bibliographic_title":"Biological & Pharmaceutical Bulletin"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The purpose of this study was to modify the biodistribution and pharmacokinetics of tilisolol, a β-blocker, using the palmitoyl prodrug approach. After intravenous administration of tilisolol and O-palmitoyl tilisolol in rats, drug concentrations were determined in blood, bile, urine, and several tissues. The concentration-time profiles of tilisolol and O-palmitoyl tilisolol were analyzed pharmacokinetically. The blood concentrations of O-palmitoyl tilisolol after intravenous administration of O-palmitoyl tilisolol were about 10-fold higher than those of tilisolol after intravenous administration of tilisolol. The biliary excretion rates of O-palmitoyl tilisolol and tilisolol after intravenous administration of O-palmitoyl tilisolol were about 10- to 100-fold larger than those of tilisolol after intravenous administration of tilisolol. In addition, the hepatic uptake clearance of O-palmitoyl tilisolol after intravenous administration of O-palmitoyl tilisolol was 3.6-fold higher than that of tilisolol after the intravenous administration of tilisolol. In the in vitro experiments, it was demonstrated that the distribution ratios between blood cells and plasma (blood/plasma) of O-palmitoyl tilisolol and tilisolol was 95.7 and 55.5%, respectively. These findings suggest that O-palmitoyl tilisolol exists as a binding form with biological components, especially blood cells, in systemic circulation. In conclusion, the palmitoyl prodrug approach is useful as a drug delivery system to deliver the parent drug to the liver.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Biological & Pharmaceutical Bulletin v.25(8) p.1072-1076, 2002","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Pharmaceutical Society of Japan"}]},"item_2_relation_11":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"12186412","subitem_relation_type_select":"PMID"}}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1248/bpb.25.1072","subitem_relation_type_select":"DOI"}}]},"item_2_relation_42":{"attribute_name":"関係URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"http://dx.doi.org/10.1248/bpb.25.1072"}]}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA10885497","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"09186158","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"1347-5215","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kawakami, Shigeru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ohshima, Nao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hirayama, Ryu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hirai, Masami"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kitahara, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sakaeda, Toshiyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mukai, Takahiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nishida, Koyo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakamura, Junzo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakashima, Mikiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sasaki, Hitoshi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-24"}],"displaytype":"detail","filename":"BPBul25_1072.pdf","filesize":[{"value":"80.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"BPBul25_1072.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/23161/files/BPBul25_1072.pdf"},"version_id":"741b3b75-0387-4fdb-ad26-6f6f4f0bc9e6"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"prodrug","subitem_subject_scheme":"Other"},{"subitem_subject":"tilisolol","subitem_subject_scheme":"Other"},{"subitem_subject":"pharmacokinetic","subitem_subject_scheme":"Other"},{"subitem_subject":"liver","subitem_subject_scheme":"Other"},{"subitem_subject":"β-blockers","subitem_subject_scheme":"Other"},{"subitem_subject":"stability","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Biodistribution and Pharmacokinetics of O-Palmitoyl Tilisolol, a Lipophilic Prodrug of Tilisolol, after Intravenous Administration in Rats","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Biodistribution and Pharmacokinetics of O-Palmitoyl Tilisolol, a Lipophilic Prodrug of Tilisolol, after Intravenous Administration in Rats"}]},"item_type_id":"2","owner":"2","path":["74"],"pubdate":{"attribute_name":"公開日","attribute_value":"2007-10-12"},"publish_date":"2007-10-12","publish_status":"0","recid":"23161","relation_version_is_last":true,"title":["Biodistribution and Pharmacokinetics of O-Palmitoyl Tilisolol, a Lipophilic Prodrug of Tilisolol, after Intravenous Administration in Rats"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T00:58:26.660216+00:00"}